B
Brita Pekarsky
Researcher at University of South Australia
Publications - 41
Citations - 484
Brita Pekarsky is an academic researcher from University of South Australia. The author has contributed to research in topics: Health care & Shadow price. The author has an hindex of 14, co-authored 41 publications receiving 458 citations. Previous affiliations of Brita Pekarsky include Flinders University & Baker IDI Heart and Diabetes Institute.
Papers
More filters
Journal ArticleDOI
Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified.
Robyn L. Ward,Jenny Turner,Rachel Williams,Brita Pekarsky,Deborah Packham,M. Velickovic,Alan P. Meagher,Terence O'Connor,Nicholas J. Hawkins +8 more
TL;DR: Routine screening of colorectal cancers by mismatch repair IHC identifies individuals at low risk of relapse, and can prevent unnecessary adjuvant treatments in a significant number of individuals.
Journal ArticleDOI
Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room
Simon Eckermann,Brita Pekarsky +1 more
TL;DR: This work critically examines the conditions under which displaced services would represent an economically meaningful threshold value for the effects of a new technology as part of a reimbursement process when budgets are fixed and identifies the most cost-effective alternative strategy for reimbursement.
Journal ArticleDOI
Assessing the Impact of the Australia-United States Free Trade Agreement (AUSFTA) on Australian and Global Medicines Policy
Thomas Faunce,Evan Doran,David Henry,Peter Drahos,Peter Drahos,Andrew Searles,Brita Pekarsky,Warwick Neville +7 more
TL;DR: To the extent that the AUSFTA medicines provisions may represent animportant precedent in a global strategy by industry on cost-effectiveness evaluation of pharmaceuticals, the study will be of great interest to policy makers in other jurisdictions.
Journal ArticleDOI
Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.
Michael J. Sorich,John D. Horowitz,Wassana Sorich,Michael D. Wiese,Brita Pekarsky,Jonathan Karnon +5 more
TL;DR: Ticagrelor is likely to be cost-effective even for individuals not carrying a CYP2C19 LoF allele, and the incremental cost-effectiveness compared with the genotyping strategy was generally within what is considered acceptable.
Journal ArticleDOI
Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy
Thomas Faunce,Evan Doran,Evan Doran,David Henry,David Henry,Peter Drahos,Andrew Searles,Andrew Searles,Brita Pekarsky,Brita Pekarsky,Warwick Neville +10 more
TL;DR: The AUSFTA medicines provisions may represent animportant precedent in a global strategy by industry on cost-effectiveness evaluation of pharmaceuticals, the study will also beof great interest to policy makers in other jurisdictions as mentioned in this paper.